相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum
J. Lian et al.
CELL DEATH AND DIFFERENTIATION (2011)
SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
K. N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists
K. C. Goldsmith et al.
CELL DEATH AND DIFFERENTIATION (2010)
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
Andrew J. Armstrong et al.
EUROPEAN JOURNAL OF CANCER (2010)
AT-101 (R-(-)-Gossypol Acetic Acid) Enhances the Effectiveness of Androgen Deprivation Therapy in the VCaP Prostate Cancer Model
Natalie McGregor et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
W. K. Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
Rebecca Suk Heist et al.
Journal of Thoracic Oncology (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2009)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Yang Meng et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2
Benjamin D. Zeitlin et al.
CANCER RESEARCH (2006)
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
DP Petrylak et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
